MetaADEDB 2.0 @ LMMD
Fluorescein
(YKGGGCXBWXHKIZ-UHFFFAOYSA-N)
Structure
SMILES
Oc1ccc2c(c1)oc1c(c2c2ccccc2C(=O)O)ccc(=O)c1
Molecular Formula:
C20H12O5
Molecular Weight:
332.306
Log P:
3.9686
Hydrogen Bond Acceptor:
5
Hydrogen Bond Donor:
2
TPSA:
87.74
CAS Number(s):
518-45-6
Synonym(s)
1.
Fluorescein
2.
Fluorescein Sodium
3.
Sodium Fluorescein
4.
C.I. 45350
5.
Colircusi Fluoresceina
6.
D & C Yellow No. 7
7.
D & C Yellow No. 8
8.
D and C Yellow No. 7
9.
D and C Yellow No. 8
10.
D&C Yellow No. 7
11.
D&C Yellow No. 8
12.
Diofluor
13.
Disodium Fluorescein
14.
Fluor-I-Strip A.T.
15.
Fluorescein Dipotassium Salt
16.
Fluorescein Disodium Salt
17.
Fluorescein Monosodium Salt
18.
Fluorescite
19.
Fluorescéine sodique Faure
20.
Fluorets
21.
Ful-Glo
22.
Funduscein
23.
Minims Fluorescein Sodium
24.
Minims Fluoresceine
25.
Minims Stains
26.
Optifluor Diba
27.
Uranine
28.
Dipotassium Salt, Fluorescein
29.
Disodium Salt, Fluorescein
30.
Fluor I Strip A.T.
31.
Fluorescein Sodium, Minims
32.
Fluorescein, Disodium
33.
Fluorescein, Sodium
34.
Fluoresceina, Colircusi
35.
Fluoresceine, Minims
36.
Ful Glo
37.
Monosodium Salt, Fluorescein
38.
Sodium, Fluorescein
External Link(s)
MeSHD019793
PubChem Compound3383
129856003
BindingDB50143424
CHEMBLCHEMBL177756
ZINC3872582
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1NauseaFAERS: 26
Canada Vigilance: 5
Canada Vigilance
US FAERS
2Anaphylactic shockFAERS: 18
Canada Vigilance: 1
Canada Vigilance
US FAERS
3DizzinessFAERS: 14
Canada Vigilance: 1
Canada Vigilance
US FAERS
4SyncopeFAERS: 14
Canada Vigilance: 1
Canada Vigilance
US FAERS
5Cardiac ArrestFAERS: 11US FAERS
6CyanosisFAERS: 11US FAERS
7UrticariaFAERS: 11
Canada Vigilance: 2
Canada Vigilance
US FAERS
8Chest discomfortFAERS: 10
Canada Vigilance: 1
Canada Vigilance
US FAERS
9HypersensitivityFAERS: 10US FAERS
10PruritusFAERS: 10
Canada Vigilance: 1
Canada Vigilance
US FAERS
11Respiratory arrestFAERS: 10US FAERS
12Cold sweatFAERS: 7US FAERS
13HypotensionFAERS: 7US FAERS
14Cerebrovascular accidentFAERS: 6US FAERS
15ChillsFAERS: 6US FAERS
16DysphoniaFAERS: 5US FAERS
17FatigueFAERS: 5US FAERS
18MalaiseFAERS: 5US FAERS
19SneezingFAERS: 5US FAERS
20StuporFAERS: 5US FAERS
21TachycardiaFAERS: 5US FAERS
22Urinary IncontinenceFAERS: 5US FAERS
23VomitingFAERS: 5
Canada Vigilance: 1
Canada Vigilance
US FAERS
24AstheniaFAERS: 4US FAERS
25Blood pressure immeasurableFAERS: 4US FAERS
26Chest PainFAERS: 4US FAERS
27DiscomfortFAERS: 4US FAERS
28PalpitationsFAERS: 4US FAERS
29Unresponsive to stimuliFAERS: 4US FAERS
30VertigoFAERS: 4US FAERS
31Visual ImpairmentFAERS: 4US FAERS
32Feeling abnormalFAERS: 3US FAERS
33Foaming at mouthFAERS: 3US FAERS
34Increased bronchial secretionFAERS: 3US FAERS
35MydriasisFAERS: 3US FAERS
36PallorFAERS: 3US FAERS
37ShockFAERS: 3US FAERS
38Anaphylactoid ReactionFAERS: 2US FAERS
39Angina PectorisFAERS: 2US FAERS
40AngioedemaFAERS: 2US FAERS
41BradycardiaFAERS: 2US FAERS
42Burning sensationFAERS: 2US FAERS
43Cerebellar infarctionFAERS: 2US FAERS
44Contrast media allergyFAERS: 2US FAERS
45CryingFAERS: 2US FAERS
46DysarthriaFAERS: 2US FAERS
47ErythemaFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
48FlushingFAERS: 2US FAERS
49Hypertensive crisisFAERS: 2US FAERS
50HypoxiaFAERS: 2US FAERS
51Lip swellingFAERS: 2US FAERS
52Myocardial InfarctionFAERS: 2US FAERS
53Respiratory FailureFAERS: 2US FAERS
54Throat irritationFAERS: 2US FAERS
55TremorFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
56VasculitisFAERS: 2US FAERS
57Ventricular FibrillationFAERS: 2US FAERS
58Abdominal discomfortFAERS: 1US FAERS
59Acute left ventricular failureFAERS: 1US FAERS
60Acute myocardial infarctionFAERS: 1US FAERS
61AnxietyFAERS: 1US FAERS
62Apallic syndromeFAERS: 1US FAERS
63Apparent life threatening eventFAERS: 1US FAERS
64AsthmaFAERS: 1US FAERS
65Atrial FibrillationFAERS: 1US FAERS
66BlepharospasmFAERS: 1US FAERS
67Blood lactate dehydrogenase increasedFAERS: 1US FAERS
68BronchospasmFAERS: 1US FAERS
69Consciousness fluctuatingFAERS: 1US FAERS
70DiplopiaFAERS: 1US FAERS
71DroolingFAERS: 1US FAERS
72Electrocardiogram ST-T segment depressionFAERS: 1US FAERS
73Eye irritationFAERS: 1US FAERS
74Facial paralysisFAERS: 1US FAERS
75General physical health deteriorationFAERS: 1US FAERS
76HeadacheFAERS: 1US FAERS
77HypersomniaFAERS: 1US FAERS
78Iatrogenic injuryFAERS: 1US FAERS
79Immediate post-injection reactionFAERS: 1US FAERS
80IncontinenceFAERS: 1US FAERS
81InfectionFAERS: 1US FAERS
82Injection Site ReactionFAERS: 1US FAERS
83Intracranial HypotensionFAERS: 1US FAERS
84KetoacidosisFAERS: 1US FAERS
85No reaction on previous exposure to drugFAERS: 1US FAERS
86Ocular discomfortFAERS: 1US FAERS
87Ocular icterusFAERS: 1US FAERS
88Oral pruritusFAERS: 1US FAERS
89PO2 decreasedFAERS: 1US FAERS
90PancreatitisFAERS: 1US FAERS
91Peripheral swellingFAERS: 1US FAERS
92Post procedural complicationFAERS: 1US FAERS
93Procedural complicationFAERS: 1US FAERS
94Pulmonary congestionFAERS: 1US FAERS
95Rash erythematousFAERS: 1US FAERS
96Rectal tenesmusFAERS: 1US FAERS
97RestlessnessFAERS: 1US FAERS
98RetchingFAERS: 1US FAERS
99SomnolenceFAERS: 1US FAERS
100StridorFAERS: 1US FAERS
101Swelling of eyelidFAERS: 1US FAERS
102SwellingFAERS: 1US FAERS
103Urinary RetentionFAERS: 1US FAERS
104Viral myocarditisFAERS: 1US FAERS
105WheezingFAERS: 1US FAERS
106YawningFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.